Hepatitis Forums
Fatty Liver Disease Main Forums => Nonalcoholic Steatohepatitis (NASH) => Topic started by: Hep Editors on April 03, 2020, 12:56:32 pm
-
Two experimental medications evaluated for non-alcoholic steatohepatitis (NASH) did not improve liver fibrosis as intended, while another was discontinued because of its potential for drug interactions, according to recent company announcements.
The failure of these three candidates, along with disappointing results presented last month at The Liver Meeting, underscore the difficulty of treating this complex but increasingly common metabolic condition.
NASH and its less severe form, non-alcoholic fatty liver disease (NAFLD), are responsible for a growing proportion of advanced liver disease. The accumulation of fat in the liver triggers inflammation, which over time can lead to fibrosis (buildup of scar tissue), cirrhosis and liver cancer. With no effective approved medical therapies, management relies on lifestyle changes such as weight loss and exercise.
For more...
https://www.hepmag.com/article/companies-announce-nash-drug-disappointments